The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab

IL-6 contributes significantly to the chronic inflammatory process of rheumatoid arthritis (RA). Tocilizumab, a humanized anti-human IL-6 receptor antibody that blocks the signaling originated by the IL-6/IL-6R complex, is an effective treatment. However, predictors of the response to tocilizumab are still required. We aimed to combine IL-6 and soluble IL-6R (sIL-6R) levels to identify groups of responses

Source: Seminars in Arthritis and Rheumatism - November 1, 2017 Category: Rheumatology Authors: Cesar Diaz-Torne, M. Angels Ortiz, Patricia Moya, M. Victoria Hernandez, Delia Reina, Ivan Castellvi, Juan Jose De Agustin, Diana de la Fuente, Hector Corominas, Raimon Sanmarti, Carlos Zamora, Elisabet Cant ó, Silvia Vidal Source Type: research